Intellia Therapeutics, Inc. (FRA:38I)

Intellia Therapeutics Statistics

Total Valuation

FRA:38I has a market cap or net worth of EUR 898.03 million. The enterprise value is 404.83 million.

Market Cap	898.03M
Enterprise Value	404.83M

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	115.83M
Shares Outstanding	n/a
Shares Change (YoY)	+9.22%
Shares Change (QoQ)	+6.22%
Owned by Insiders (%)	1.48%
Owned by Institutions (%)	85.64%
Float	110.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	18.32
PB Ratio	1.41
P/TBV Ratio	1.41
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.07
EV / Sales	8.16
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.15

Financial Position

The company has a current ratio of 6.21, with a Debt / Equity ratio of 0.13.

Current Ratio	6.21
Quick Ratio	5.57
Debt / Equity	0.13
Debt / EBITDA	n/a
Debt / FCF	-0.24
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -52.11% and return on invested capital (ROIC) is -31.32%.

Return on Equity (ROE)	-52.11%
Return on Assets (ROA)	-28.51%
Return on Invested Capital (ROIC)	-31.32%
Return on Capital Employed (ROCE)	-57.57%
Revenue Per Employee	121,665
Profits Per Employee	-942,830
Employee Count	403
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.26% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-45.26%
50-Day Moving Average	13.67
200-Day Moving Average	9.90
Relative Strength Index (RSI)	38.48
Average Volume (20 Days)	1,240

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.99

Income Statement

In the last 12 months, FRA:38I had revenue of EUR 49.03 million and -379.96 million in losses. Loss per share was -3.62.

Revenue	49.03M
Gross Profit	-300.31M
Operating Income	-408.02M
Pretax Income	-379.96M
Net Income	-379.96M
EBITDA	-397.39M
EBIT	-408.02M
Loss Per Share	-3.62

Balance Sheet

The company has 435.56 million in cash and 83.50 million in debt, giving a net cash position of 487.42 million.

Cash & Cash Equivalents	435.56M
Total Debt	83.50M
Net Cash	487.42M
Net Cash Per Share	n/a
Equity (Book Value)	637.88M
Book Value Per Share	5.51
Working Capital	416.11M

Cash Flow

In the last 12 months, operating cash flow was -349.99 million and capital expenditures -1.69 million, giving a free cash flow of -351.68 million.

Operating Cash Flow	-349.99M
Capital Expenditures	-1.69M
Free Cash Flow	-351.68M
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	-832.16%
Pretax Margin	-774.94%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:38I does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.22%
Shareholder Yield	-9.22%
Earnings Yield	-42.31%
FCF Yield	-39.16%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:38I has an Altman Z-Score of -0.72 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.72
Piotroski F-Score	3